Drugs / morinidazole
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03391440 | Sep 2016 → Dec 2018 | pelvic inflammatory disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03380793 | Sep 2016 → Oct 2018 | appendicitis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | morinidazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03391440 ↗ |
| Known as | Morponidazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL3884248 ↗ |
| Modality | Small molecule | — CHEMBL3884248 ↗ |
| Route | Intravenous | “500 mg intravenous” NCT03380793 ↗ |